CCS
LRMR icon

Concentric Capital Strategies’s Larimar Therapeutics LRMR Stock Holding History

Concentric Capital Strategies’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-123,325
Closed -$936K – 363
2024
Q1 		$936K Buy
+123,325
New +$961K 0.05% 246

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Concentric Capital Strategies's LRMR Position: Q2 2024 in Review

Concentric Capital Strategies sold out of Larimar Therapeutics (LRMR) in Q2 2024, closing a stake of 123,325 shares — an estimated $936K sold.

Concentric Capital Strategies first reported a position in LRMR in Q1 2024 and held it in 1 quarter. The position peaked at $936K in Q1 2024. 107 funds tracked by Wall St. Rank hold LRMR as of Q2 2024.

  • Concentric Capital Strategies reported no remaining Larimar Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Concentric Capital Strategies sold 123,325 Larimar Therapeutics shares in Q2 2024, an estimated $936K.
  • Concentric Capital Strategies first reported a position in Larimar Therapeutics in Q1 2024 and held it in 1 quarter.
  • Concentric Capital Strategies's Larimar Therapeutics position peaked at $936K in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2024.

Based on Concentric Capital Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.